Shares of Aeterna (AEZS) are now soaring, up over 18% on the back of earlier reports that it's...

|By:, SA News Editor

Shares of Aeterna (AEZS) are now soaring, up over 18% on the back of earlier reports that it's reached an agreement with the FDA on a Special Protocol Assessment for Phase 3 trials of its endometrial cancer treatment doxorubicin eptide conjugate, or AEZS-108. The company says the agreement provides it with "a clearly defined development and regulatory pathway."